From Name:
From Email:
To Name:
To Email:

Optional Message:

Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease

from AAGP

Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June. Approximately 300 patients are expected to be enrolled in this 12-week, randomized, double-blind, placebo-controlled trial. Additional information about the trial will be available in the near future at and will be updated periodically following initiation of the study. For more information, go to more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063